Project Grant HT94252410201
Award Date
3/15/24
Completion Date
3/14/26
Dollars Obligated
$1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
Brigham & Women's Hospital Inc. was awarded an $895,001 project grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program. The two-year award will support in vitro studies targeting proinflammatory mediators to restore regulatory T cell homeostatic expansion and function in amyotrophic lateral sclerosis. The research aims to develop surrogates for in vivo applications in investigating medical solutions for the...
The $925,344 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to Brigham & Womens Hospital Inc. will support research to "MODULATE MICROGLIA AND ASTROCYTES TO TREAT ALZHEIMER'S DISEASE AND RELATED DEMENTIAS". The 3-year grant, awarded on April 15, 2024, will fund innovative biomedical research focused on developing new treatments for Alzheimer's disease and other neurodegenerative conditions by investigating the...
The University of Massachusetts Medical School was awarded a $836,992 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on August 1, 2025, will fund research to investigate the effects of military-associated environmental toxins on motor neurons and glial cells in sporadic amyotrophic lateral sclerosis (ALS). The research aims to transform healthcare for military service members, veterans, and the broader...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
The Department of Defense's Defense Health Agency awarded a $921,600 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) to research the "Therapeutic Effects of Sulfide Catabolism and Novel Trisulfide Compounds for Amyotrophic Lateral Sclerosis." The grant, under the Military Medical Research and Development program (CFDA 12.420), supports foundational biomedical research aimed at developing novel treatments for amyotrophic lateral sclerosis (ALS)....
The Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts was awarded a $1,296,751 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on June 1, 2024, will fund a 2-year research project titled "Electrical Impedance Myography via the Myolex mScan as an ALS Biomarker." The goal of the project is to evaluate a novel diagnostic approach using electrical impedance myography...
The University of Massachusetts Medical School has been awarded a $987,615 federal Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from September 30, 2024 to September 29, 2026, supports the "Development of Chimeric Antigen Receptor T Regulatory Cells (CAR Tregs) for the Treatment of Amyotrophic Lateral Sclerosis." This project aims to advance research into new therapeutic approaches for...
The Department of Defense's Defense Health Agency awarded a $263,598 project grant to Brigham & Women's Hospital Inc. in Boston, MA to conduct research for the "LAM-TARGETING NANOPARTICLE-ASSISTED AND BASE EDITOR-ENABLED GENE THERAPY FOR LYMPHANGIOLEIOMYOMATOSIS" project. This 24-month grant, which runs from August 1, 2024 to July 31, 2026, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to develop novel gene therapy...
This federal Project Grant award of $1,072,079.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Massachusetts Institute of Technology (MIT) to develop diagnostic biomarkers for clinical subtypes of amyotrophic lateral sclerosis (ALS). The research aims to advance the understanding and treatment of ALS, a neurological disorder, with potential benefits for military service members and the broader public....
The U.S. Defense Health Agency awarded a $1,134,000 Project Grant to President and Fellows of Harvard College (Harvard University) under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "NOVEL BRAIN SHUTTLE-MEDIATED ANTI-TDP-43 THERAPEUTICS FOR AMYOTROPHIC LATERAL SCLEROSIS," supports research to develop novel treatments for amyotrophic lateral sclerosis (ALS) by leveraging brain shuttle technologies. The project will be conducted at Harvard...